Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

SYNGENE's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 44.267765
debtToEquity 12.226000
earningsGrowth 0.144000
revenueGrowth 0.107000
grossMargins 0.681930
operatingMargins 0.114350
trailingEps 12.630000
forwardEps 16.850000

SYNGENE's low Debt-to-Equity ratio signals the company is not over-leveraged, meaning it has a conservative approach to debt. This reduces financial risk and indicates a stable financial foundation, providing flexibility and security, which can appeal to investors seeking lower-risk investments.
With positive earnings and revenue growth, Syngene International Limited is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.
Syngene International Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

SYNGENE's price projections have been revised downward over time, reflecting a shift in sentiment among analysts. The steady decline in projections points to a more cautious outlook on the company's future performance.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


There were 21 SYNGENE sales transactions, at market price of 847.76904296875.There were no sell transactions during the period under consideration.More buys than sells have been occurring around the current price levels of Syngene International Limited, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


Analysts have been favoring Syngene International Limited with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning Syngene International Limited as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.